Texas HB 2529: Relating to written notification provided by drug manufacturers regarding the cause of generic insulin prescription drug unavailability.

Status: Left pending in committee (as of 2023-05-01)

State: Texas · Session: 88 · Bill: HB 2529

Subjects: DIABETES (S0486), HEALTH & HUMAN SERVICES COMMISSION (V0177), Health--Other Diseases & Medical Conditions (I0383), Insurance--Health & Accident (I0422), MEDICINE & PRESCRIPTION DRUGS (S7338)

Sponsors: Talarico

View Texas HB 2529 on LegisTrack → — full text, sponsors, votes, campaign finance, and cross-state matches.